Shire Pharmaceuticals Acquires Lotus Tissue Repair for Undisclosed Sum
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=757a8151-ac2d-4e1a-8564-d196eee86d97&Preview=1 -
Date
1/9/2013 -
Company Name
Lotus Tissue Repair -
Mailing Address
One Mifflin Place Cambridge, MA 02138 -
Company Description
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions. -
Website
http://www.lotustissuerepair.com -
Transaction Type
M&A -
Transaction Amount
Undisclosed -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Shire will purchase the company for an upfront payment and certain contingent payments based on the achievement of certain safety and development milestones.
